News

Vivodyne to Replace Animal Testing With $40 Million Funding

Business Wire
•
May 29, 2025
Vivodyne Chief Operating Officer Julie O'Shaughnessy (L) and Vivodyne CEO Andrei Georgescu (R).
Share on

Discover More Articles

view all posts
As the FDA and NIH eschew animal testing, startup raises $40 million
Vivodyne raises $40M for human tissue drug testing
Advantages and Impact of FDA’s Plan to Phase Out Animal Testing for mAbs and Other Drugs
FDA Wants a Shift Away from Animal Testing
FDA Unveils Plan to Replace Animal Testing with Organoids
Human data before the clinic.
Connect With Us
Applications
San Francisco, USA
© 2024 Vivodyne
Privacy
linkedinlinkedinxx